StreetAlpha.app
Home › Stocks › AYTU

Aytu Biopharma, Inc (AYTU)

$2.66
▲ +0.00%
LAST CLOSE · NOV 20

Aytu BioPharma sells prescription medicines for depression, ADHD and allergic conditions from its base in Denver, Colorado. It last closed at $2.66 on Nov 20, up 0.00% on the day. The next earnings report for AYTU is expected around Tue, Feb 2, 2027, after the close. For the quarter ended Sep 2026, AYTU reported EPS of -$0.20 on revenue of $14.8M, with revenue up 6.9% from a year ago. Over its last 8 reports the stock moved an average of 21.4% the session after earnings.

AI Auto Pilots
Is AYTU in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AYTU.

Key Stats

Last 12 months
Results
Revenue
$58.5M
−8.1% vs a year ago
Net income
−$20.1M
−34.3% margin
EPS (diluted)
−$1.28
Gross margin
63.3%
$37.1M gross profit
Valuation
Market cap
$28.9M
10.9M shares
P/E
–
No P/E while losing money
Price to sales
0.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$25.5M
At Sep 30
Debt
$10.5M
At Sep 30
Shareholder equity
$31.6M
Shares outstanding
10.9M
At Nov 9
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $96.7M$96.7MFY2022FY2023: $107.4M$107.4MFY2023FY2024: $65.2M$65.2MFY2024FY2025: $66.4M$66.4MFY2025FY2026: $57.6M$57.6MFY2026

From AYTU's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Feb 2
Estimated date · After the close
Reported EPS
-$0.20
Quarter ended Sep 2026
Year ago EPS
-$0.08
Same quarter last year
Revenue
$14.8M
+6.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.26Dec '24Mar 2025: $0.21Mar '25Jun 2025: -$1.94Jun '25Sep 2025: -$0.08Sep '25Dec 2025: -$1.05Dec '25Mar 2026: -$0.53Mar '26Jun 2026: $0.26Jun '26Sep 2026: -$0.20Sep '26Latest -$0.20
Revenue by quarter
Dec 2024: $16.2MDec '24Mar 2025: $18.5MMar '25Jun 2025: $15.1MJun '25Sep 2025: $13.9MSep '25Dec 2025: $15.2MDec '25Mar 2026: $12.4MMar '26Jun 2026: $16.1MJun '26Sep 2026: $14.8MSep '26Latest $14.8M
How AYTU moved after its last 8 reports
Average move the session after a report ±21.4%
Nov 16, 2026After the close+46.1%
Sep 22, 2026After the close+2.2%
May 13, 2026After the close+0.9%
Apr 2, 2026After the close−0.8%
Feb 3, 2026After the close−10.3%
Nov 13, 2025After the close+1.5%
Sep 23, 2025After the close−17.9%
May 14, 2025After the close+91.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AYTUStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on AYTU: 0 upgrades, 1 downgrade, 0 initiations
Lake Street CapitalDowngrade
Nov 20Hold 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on AYTU
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AYTU

Technical Analysis

AYTU · as of the Nov 20 close · updated each morning
Turning up, overbought

The stock is 24% above its 20 day and 23% above its 50 day average. It is 14% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 80), overbought. The nearest support is the Pivot S1 at $2.65, and the nearest resistance the swing high (Nov 17) at $2.67.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchOverbought
VolatilityHigh, 4.9%/day
Key levels
$3.0652 week high+15.0%
$2.67Swing high (Nov 17)+0.4%
$2.66Pivot R1+0.0%
$2.66Pivot+0.0%
$2.66Last close
$2.65Pivot S1−0.4%
$2.28200 day average−14.3%
$2.25Swing low (Aug 13)−15.4%
$2.14100 day average−19.5%
$2.0550 day average−22.9%
$2.0320 day average−23.7%
$1.7552 week low−34.2%
Indicators
RSI (14)79.51Overbought above 70Overbought
MACD0.13Above its signal lineBullish
Stochastic98.9Near the top of its rangeOverbought
ADX (14)30.2Trending up
Williams %R-1.1Oversold below −80, overbought above −20Overbought
CCI (20)166.4Oversold below −100, overbought above 100Overbought
Rate of change+45.4%Change over 10 sessionsBullish
ATR (14)$0.13Typical daily range, 4.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AYTU

What happened before

See how AYTU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AYTU usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AYTU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AYTUHow many large options trades hit AYTU, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AYTU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼10 buying vs 13 selling
  • ▼Held by funds -11.1 pts
  • ▼Funds holding -2
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3638−5.3%
In funds' top 1000–
Held by funds34.2%45.3%−11.1 pts
New / increased3 / 73 / 12−33.3%
Reduced / sold out8 / 55 / 2+85.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AYTU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AYTU Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 9, 2025Joshua R. DisbrowCEOBuy66,666$1.50$100K
Jun 9, 2025Jarrett DisbrowChief Business OfficerBuy16,666$1.50$25K
Feb 28, 2025Joshua R. DisbrowCEOBuy15,000$1.30$20K
Every insider buy and sale for AYTU over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AYTU insider trades →

From SEC Form 4 filings by AYTU's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AYTU is in one of them and how their past AYTU trades turned out.

AYTU in the AI portfolios
Loading…

AYTU News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AYTU in an article yet. Here's the latest on the wider market.

AYTU in the news

About Aytu Biopharma

Aytu BioPharma is a pharmaceutical company based in Denver, Colorado, that markets and sells prescription medicines for central nervous system conditions. Its main product is EXXUA, a treatment for major depressive disorder in adults. The company also sells ADHD medicines, Adzenys and Cotempla, and Karbinal, an antihistamine suspension used to treat allergic conditions. It sells its products mainly through wholesalers and pharmacies.

Headquarters
Denver, CO